Estradiol

Generic Name: Estradiol

Brand Names: Activella 1/0.5 28 Day, Activelle, Amabelz 0.5/0.1 28 Day, Angeliq 0.25/0.5 28 Day, Bijuva, Climara, Climara Pro, Combipatch, Divigel, Dotti, Elestrin, Estalis, Estrace, Estradot, Estring, Estrogel, Etyqa 0.5/0.1 28 Day, Evamist, Imvexxy 4 Mcg Starter Pack, Lopreeza 1/0.5 28 Day, Lyllana, Menostar, Mimvey, Minivelle, Myfembree, Oesclim, Oriahnn 28 Day Kit, Prefest 30 Day, Vagifem, Vivelle, Yuvafem

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₄O_₂

CAS Number: 50-28-2

Unique Ingredient Identifier: 4TI98Z838E

Background: Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays,...

Indication: Estradiol is indicated in various preparations for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. It is also used for the treatment of breast cancer (...

Associated Conditions: Atrophic Vaginitis, Breast Cancer, Breast engorgement caused by Postpartum state, Heavy Menstrual Bleeding, Hypogonadism female, Kraurosis Vulvae, Metastatic Breast Cancer, Osteoporosis, Postmenopausal Osteoporosis, Premature Ovarian Failure (POF), Prostate Cancer, Severe Pain, Urogenital atrophy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Advanced androgen dependent Prostate cancer, Female castration, Hypoestrogenism

Associated Therapies: Contraception, Hormone Replacement Therapy, Palliative Treatment

Clinical Trials

Endometriosis drug research, long underfunded, confronts familiar problems in women's health

Ally Schott's early endometriosis diagnosis at 12 led to limited treatment options and self-taught research. Despite its prevalence affecting 10% of women globally, endometriosis remains underfunded and poorly understood, with only two new drugs approved in the U.S. for pain management in the past decade. Women's health research generally suffers from insufficient funding and information deficits, hindering drug development. Recent federal efforts, including a $100 million investment by the Biden administration, aim to address these gaps, but future priorities under a new administration remain uncertain.

drugs.com

a month ago

Short-Term Hormone Therapy for Menopause Won't Harm Women's Brains

Four years of hormone replacement therapy (HRT) for menopause causes no harm to the brain, even 10 years after stopping, according to a study by Carey Gleason's team at the University of Wisconsin-Madison. Published in PLOS Medicine, the research found no cognitive decline among women who had taken HRT, but also no cognitive benefits, indicating HRT should not be seen as a means to boost neurological health.

medcitynews.com

2 months ago

Expands Women's Health Options with New Birth Control and Menopause Offerings

GoodRx launched an e-commerce platform with Opill, the first OTC birth control pill in the U.S., offering home delivery. The platform also introduced affordability programs for Pfizer's menopause hormone therapies, amid rising medication costs and the 'Pink Tax' in healthcare.

globenewswire.com

2 months ago

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals launched Estradiol Gel, 0.06% after FDA approval, aiming to provide a limited-competition product with annual U.S. sales of $16.7 million.

openpr.com

3 months ago

Red Biotechnology Market Global Trends Evaluation

The Red Biotechnology Market is projected to grow at a CAGR of 5.2% by 2031, driven by advancements in pharmaceuticals, vaccines, and diagnostics. Key players include Hoffmann-La Roche, Ltd., Merck KGaA, and Regeneron Pharmaceuticals, Inc. The market is segmented by product type, application, and end user, with regional focus on North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.